Risk of Ovarian Malignancy Algorithm (ROMA) LIS Code: ROMA
Assess your ovarian cancer risk with the ROMA test. Measures HE4 and CA-125 biomarkers to evaluate the likelihood of malignant ovarian tumours.
What's included in this profile
- A protein that can be raised with ovarian conditions
- Used alongside imaging to assess ovarian masses
- Can also be raised in some noncancerous conditions
- A protein used alongside CA 125 in ovarian risk assessment
- Helps improve the accuracy of ovarian mass evaluation
- Combined with CA 125 in the ROMA risk calculation
- Risk of Ovarian Malignancy Algorithm for postmenopausal women
- Combines CA 125 and HE4 into a single risk estimate
- Helps guide further investigation of an ovarian mass
- Risk of Ovarian Malignancy Algorithm for premenopausal women
- Combines CA 125 and HE4 into a single risk estimate
- Helps guide further investigation of an ovarian mass
About this profile
Sample Requirements:
Turnaround Time:
5 days
The Risk of Ovarian Malignancy Algorithm (ROMA) is a specialized blood test designed to assess the likelihood of ovarian cancer in women. By analyzing specific tumor markers, this profile provides a comprehensive risk evaluation, helping healthcare providers differentiate between benign and malignant ovarian conditions. The ROMA test combines levels of Cancer Antigen 125 (CA 125) and Human Epididymis Protein 4 (HE4) with patient menopausal status (ROMA-PRE for premenopausal and ROMA-POST for postmenopausal women), offering a highly accurate prediction of ovarian malignancy risk.
Indications for testing
The ROMA test is indicated for women who present with symptoms suggestive of ovarian cancer, such as persistent bloating, pelvic pain, abnormal menstruation, or a noticeable mass in the pelvic area. It is also recommended for women with a family history of ovarian or breast cancer, as well as those undergoing routine monitoring for known ovarian cysts or other gynecological abnormalities.
What can be detected?
The Risk of Ovarian Malignancy Algorithm (ROMA) helps to:
Evaluate ovarian cancer risk: By measuring CA 125 and HE4, the ROMA test assesses the likelihood of ovarian malignancy, providing valuable guidance for further diagnostic procedures such as imaging or biopsy.
Differentiate between benign and malignant conditions: ROMA helps healthcare providers distinguish between non-cancerous ovarian cysts and those that may require urgent intervention, aiding in the decision-making process.
Monitor treatment response: In women with diagnosed ovarian cancer, this test can help track disease progression and response to treatment, allowing for adjustments in care as needed.
Who is this test for?
The ROMA test is particularly useful for women at high risk of ovarian cancer due to symptoms, family history, or existing ovarian abnormalities. It is also valuable for women undergoing evaluation for pelvic masses or who are being monitored for recurrence after treatment for ovarian cancer.
Fasting requirements
No fasting is required for the ROMA test. However, it is important to follow any specific instructions provided by your healthcare provider to ensure accurate results.
